CSF2 and Miyoshi myopathy: In a phase I/IIa, single institution study (NCT02275416), 12 patients with MM received ipilimumab plus repeated UV1 vaccinations, with Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) as an adjuvant.